We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 31, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Chevron (CVX - Free Report) , Wells Fargo (WFC - Free Report) , Eli Lilly (LLY - Free Report) , FedEx (FDX - Free Report) and Valero Energy (VLO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Chevron, Wells Fargo and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron, Wells Fargo and Eli Lilly. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Chevron’s shares have risen +17.3% in the past year, outperforming the Zacks Integrated Oil industry's +14.8% increase, while larger rival Exxon Mobil has seen its scrip go up a meagre 1.3% over the same time period.
The supermajor has been a beneficiary of the recovery in commodity prices, which helped its upstream unit profits to double from a year ago. Further, Chevron’s high-quality Permian acreage continues to drive production. Importantly, cash flow from operations, at $5 billion, were more than $1 billion higher than a year ago.
However, the Zacks analyst remains worried over a drop in Chevron’s downstream segment earnings on weaker margins, while exposure to production in the vulnerable and violence-prone regions in Nigeria poses additional risk. Hence, investors are advised to wait for a better entry point before buying shares in Chevron.
Wells Fargo’s shares have underperformed the Zacks Major Banks industry over the last six months (-5.7% vs. -2.3%). The company possesses a decent earnings surprise history, having beaten the Zacks Consensus Estimate in two of the trailing four quarters.
Recently, the bank entered into a consent order with OCC and CFPB for paying $1 billion as civil penalty related to auto-loan issues. Also, Wells Fargo was slapped with new sanctions, including a cap on the assets position by the Federal Reserve. Though continued growth in loans and deposits, lower tax rate and expansions will likely support the bank’s growth profile, the crisis related to the revelation of illegally opening millions of illegal accounts in 2016 will take some time to alleviate.
Shares of Buy-rated Eli Lilly have outperformed the Zacks Large-Cap Pharmaceuticals industry in the last year (+3.6% vs. -0.8%). The Zacks analyst thinks Lilly’s presence across a wide range of therapeutic areas provides support in the face of generic competition. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018.
Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. Also, competitive pressure on Lilly’s drugs is expected to rise this year.
Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018.
Other noteworthy reports we are featuring today include FedEx and Valero Energy.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero
For Immediate Release
Chicago, IL – May 31, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Chevron (CVX - Free Report) , Wells Fargo (WFC - Free Report) , Eli Lilly (LLY - Free Report) , FedEx (FDX - Free Report) and Valero Energy (VLO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Chevron, Wells Fargo and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron, Wells Fargo and Eli Lilly. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Chevron’s shares have risen +17.3% in the past year, outperforming the Zacks Integrated Oil industry's +14.8% increase, while larger rival Exxon Mobil has seen its scrip go up a meagre 1.3% over the same time period.
The supermajor has been a beneficiary of the recovery in commodity prices, which helped its upstream unit profits to double from a year ago. Further, Chevron’s high-quality Permian acreage continues to drive production. Importantly, cash flow from operations, at $5 billion, were more than $1 billion higher than a year ago.
However, the Zacks analyst remains worried over a drop in Chevron’s downstream segment earnings on weaker margins, while exposure to production in the vulnerable and violence-prone regions in Nigeria poses additional risk. Hence, investors are advised to wait for a better entry point before buying shares in Chevron.
Wells Fargo’s shares have underperformed the Zacks Major Banks industry over the last six months (-5.7% vs. -2.3%). The company possesses a decent earnings surprise history, having beaten the Zacks Consensus Estimate in two of the trailing four quarters.
Recently, the bank entered into a consent order with OCC and CFPB for paying $1 billion as civil penalty related to auto-loan issues. Also, Wells Fargo was slapped with new sanctions, including a cap on the assets position by the Federal Reserve. Though continued growth in loans and deposits, lower tax rate and expansions will likely support the bank’s growth profile, the crisis related to the revelation of illegally opening millions of illegal accounts in 2016 will take some time to alleviate.
Shares of Buy-rated Eli Lilly have outperformed the Zacks Large-Cap Pharmaceuticals industry in the last year (+3.6% vs. -0.8%). The Zacks analyst thinks Lilly’s presence across a wide range of therapeutic areas provides support in the face of generic competition. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018.
Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. Also, competitive pressure on Lilly’s drugs is expected to rise this year.
Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018.
Other noteworthy reports we are featuring today include FedEx and Valero Energy.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.